Abstract
[Machine translation] The article offers a first examination of the Pharmaceutical Package approved by the European Parliament on April 10, 2024. The first part takes stock of the legislative process that led to the approval, by the Parliament, of its position at first reading on the proposals for directives and regulations revising the general pharmaceutical legislation of the EU; in the second, there is a brief overview of the changes that occurred in the parliamentary passage, with respect to the texts dismissed by the Commission; in the third, some comments are made with respect to the profiles that concern the promotion of innovation or, if we want, of “drugs” innovative.”
| Translated title of the contribution | [Machine translation] First findings on the approval of the Pharmaceutical Package by the European Parliament (with particular reference to the promotion of innovative drugs) |
|---|---|
| Original language | Italian |
| Pages (from-to) | 793-800 |
| Number of pages | 8 |
| Journal | CORTI SUPREME E SALUTE |
| Issue number | 2 |
| Publication status | Published - 2024 |
Keywords
- The article proposes a first examination of the "Pharmaceutical Package" approved by the European Parliament on 10 April 2024. The first part looks at the legislative process that led to the approval, by the Parliament, of its position at first reading on the proposal of directive and regulation containing the revision of the general pharmaceutical legislation of the EU
- the second part provides a brief overview of the changes made during the parliamentary passage, compared to the texts approved by the Commission
- the third part formulates some observations with respect to the profiles that concern the promotion of innovation or, if we want, of "innovative drugs".